Hepatitis B virus core protein dimer‑dimer interface is critical for viral replication.
hepatitis B virus
core protein
dimer-dimer interface
capsid
replication
virion
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
31
01
2018
accepted:
07
09
2018
pubmed:
6
11
2018
medline:
29
5
2019
entrez:
3
11
2018
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) core protein (HBc) serves pivotal roles in the viral life cycle, particularly serving as the basic unit for capsid assembly, and is closely associated with HBV genome replication and progeny virion production. Previous studies have demonstrated that HBc has at least two functional interfaces; two HBc monomers form a homodimer via an intradimer interface, and then 90 or 120 homodimers form an icosahedral capsid via a dimer‑dimer interface. In the present study, the role of the HBc dimer‑dimer interface in HBV replication was investigated. A panel of residues located at the dimer‑dimer interface were identified based on the crystal structure of HBc. Native gel electrophoresis and western blotting revealed that, despite mutations in the dimer‑dimer interface, HBc formed a capsid‑like structure, whereas mutations at amino acid residues 23‑39 completely disrupted capsid assembly. Using denaturing gel electrophoresis, Southern and Northern blotting, and quantitative polymerase chain reaction, it was demonstrated that none of the mutations in the dimer‑dimer interface supported pregenomic RNA encapsidation or DNA replication. In addition, these mutants interacted with the wild-type (WT) HBc monomer and inhibited WT genome replication and virion production in a dose‑dependent manner. However, the quantity of covalently closed circular DNA in the nucleus was not affected. The present study highlighted the importance of the HBc dimer‑dimer interface for normal capsid function and demonstrated that the HBc dimer‑dimer interface may be a novel antiviral target.
Identifiants
pubmed: 30387827
doi: 10.3892/mmr.2018.9620
pmc: PMC6297743
doi:
Substances chimiques
Hepatitis B Core Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
262-270Références
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10046-50
pubmed: 1438193
J Virol. 2002 May;76(10):4848-54
pubmed: 11967301
J Virol. 2009 Nov;83(22):11616-23
pubmed: 19710138
J Virol. 2003 Jan;77(1):416-22
pubmed: 12477846
J Mol Biol. 2001 Mar 16;307(1):183-96
pubmed: 11243813
BMC Microbiol. 2005 May 27;5:33
pubmed: 15921513
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8138-43
pubmed: 15928089
Antimicrob Agents Chemother. 2002 Sep;46(9):3057-60
pubmed: 12183271
Hepatology. 1999 Jul;30(1):300-7
pubmed: 10385671
J Cell Biol. 1994 Apr;125(1):99-111
pubmed: 7908022
Epigenetics. 2011 Jun;6(6):720-6
pubmed: 21546797
Antimicrob Agents Chemother. 2013 Nov;57(11):5344-54
pubmed: 23959305
J Virol. 1997 Jan;71(1):345-53
pubmed: 8985356
J Virol Methods. 2004 Jun 15;118(2):159-67
pubmed: 15081611
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
J Virol. 1998 Jun;72(6):4997-5005
pubmed: 9573269
J Virol. 2015 Mar;89(6):3275-84
pubmed: 25568211
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9849-54
pubmed: 12909718
Antimicrob Agents Chemother. 2002 Dec;46(12):4004-8
pubmed: 12435712
N Engl J Med. 2008 Oct 2;359(14):1486-500
pubmed: 18832247
J Virol. 1989 Nov;63(11):4645-52
pubmed: 2677399
Mol Cell. 1999 Jun;3(6):771-80
pubmed: 10394365
Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68
pubmed: 10704474
J Virol. 1990 Jul;64(7):3319-30
pubmed: 2191149
Virology. 2015 May;479-480:672-86
pubmed: 25759099
Nucleic Acids Res. 2013 Jan;41(Database issue):D566-70
pubmed: 23125365
Biochemistry. 1996 Jun 11;35(23):7412-21
pubmed: 8652518
J Virol. 2006 Nov;80(22):11055-61
pubmed: 16943288
Oncogene. 2001 Oct 4;20(45):6579-86
pubmed: 11641783
Gastroenterology. 2006 Mar;130(3):823-37
pubmed: 16530522
J Clin Microbiol. 1998 Feb;36(2):531-8
pubmed: 9466771